Skip to Content

US Stem Cell Inc USRM

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

USRM is trading at a 34% discount.
Price
$0.00
Fair Value
$5.99
Uncertainty
Extreme
1-Star Price
$6.39
5-Star Price
$9.87
Economic Moat
Hvwf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if USRM is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.01
Bid/Ask
$0.00 / $0.00
Market Cap
$641.51
Volume/Avg
1,001 / 372,660

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
11

Valuation

Metric
USRM
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
USRM

Financial Strength

Metric
USRM
Quick Ratio
0.00
Current Ratio
0.00
Interest Coverage
−3.14
Quick Ratio
USRM

Profitability

Metric
USRM
Return on Assets (Normalized)
−2,007.84%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
USRM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRPnzc$553.8 Bil
VRTX
Vertex Pharmaceuticals IncWtvnvmh$108.7 Bil
REGN
Regeneron Pharmaceuticals IncYylpj$104.0 Bil
MRNA
Moderna IncHdzv$33.2 Bil
ARGX
argenx SE ADRNpy$23.6 Bil
BNTX
BioNTech SE ADRQqdg$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncLlqdmb$18.9 Bil
BMRN
Biomarin Pharmaceutical IncHdzyppv$16.7 Bil
RPRX
Royalty Pharma PLC Class ALgyqx$13.5 Bil
INCY
Incyte CorpNjwbq$13.2 Bil

Sponsor Center